Progressive Supranuclear Palsy Clinical Trial
Official title:
Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal and glial tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions. There is no effective treatment for PSP. One of the key feature in the aggregation of tau is its phosphorylation by kinases such as glycogen synthase kinase 3b (GSK3b). Recent reports have shown that valproic acid was able to inhibit the activity of GSK3b and could exert a neuroprotective effect through this inhibition. The investigators thus decided to conduct this controlled study to assess the putative neuroprotective effects in patients with PSP.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04096651 -
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Completed |
NCT00703677 -
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00382824 -
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
|
N/A | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04139551 -
Oxford Study of Quantification in Parkinsonism
|
||
Completed |
NCT02734485 -
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01110720 -
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
|
Phase 2/Phase 3 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
Completed |
NCT02460094 -
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
|
Phase 1 | |
Active, not recruiting |
NCT04993768 -
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
|
Phase 2 | |
Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
Completed |
NCT03058965 -
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
|
Early Phase 1 | |
Recruiting |
NCT02605785 -
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01353183 -
Analysis of the Enteric Nervous System Using Colonic Biopsies
|
N/A | |
Recruiting |
NCT05260151 -
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
|
||
Active, not recruiting |
NCT04658199 -
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
|
Phase 1 |